We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01431105
Recruitment Status : Recruiting
First Posted : September 9, 2011
Last Update Posted : October 26, 2016
Information provided by (Responsible Party):

September 6, 2011
September 9, 2011
October 26, 2016
July 2012
June 2018   (Final data collection date for primary outcome measure)
Safety of atorvastatin in children with coronary artery abnormalities secondary to Kawasaki disease [ Time Frame: At 6 weeks after initiation of study drug ]
Evaluation of cholesterol, liver functions, and markers of myopathy at the above time points.
Same as current
Complete list of historical versions of study NCT01431105 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics [ Time Frame: 0,1,2,6,12,24 hours at baseline; 2&6 weeks ]
    Blood will be drawn around the first dose at 0,1,2,6,12 and 24 hours and troughs will be drawn at 2 weeks and 6 weeks during the clinic visit.
  • Atorvastatin Activity [ Time Frame: Baseline, 2 weeks and 6 weeks ]
    Measures of oxidative stress will be assessed at baseline, 2 weeks and 6 weeks after study enrollment.
Not Provided
Not Provided
Not Provided
Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
Phase I/IIa Study of Pharmacokinetics and Safety of Atorvastatin in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery abnormalities that could lead to complications later in life, including heart attack. Although investigators can identify children with KD that have these coronary artery abnormalities, there is no approved additional treatment to decrease coronary artery inflammation and arrest or prevent damage to the coronary arteries. Inflammation and damage to the arterial wall is central to these coronary artery abnormalities. Statins, a class of drugs that is known for lowering cholesterol, have also been shown to decrease inflammation in general as well as at the level of the vessel wall. Therefore, the investigators propose to study the safety of the drug atorvastatin in children with coronary artery abnormalities from KD.
Not Provided
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Kawasaki Disease
Drug: Atorvastatin
Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
Other Name: Lipitor
Experimental: Atorvasatin
Atorvastatin dose titration to maximum tolerated dose
Intervention: Drug: Atorvastatin
He M, Chen Z, Martin M, Zhang J, Sangwung P, Woo B, Tremoulet AH, Shimizu C, Jain MK, Burns JC, Shyy JY. miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease. Circ Res. 2017 Jan 20;120(2):354-365. doi: 10.1161/CIRCRESAHA.116.310233. Epub 2016 Dec 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
December 2018
June 2018   (Final data collection date for primary outcome measure)

Inclusion criteria:

  1. Age ≥ 2 years to 17 years old
  2. Meets clinical criteria for KD according to American Heart Association guidelines (Table 2): Fever (T≥38oC or 100.4oC) ≥ 3 days and ≥ 2 clinical criteria with left anterior descending coronary artery/right coronary artery z-score ≥ 2.5 or an aneurysm (≥ 1.5 x the adjacent segment) of one of the coronary arteries
  3. Patient presents within the first 20 days after fever onset
  4. Parent or legal guardian able and willing to provide informed consent and subject willing and able to provide assent when appropriate.
  5. Post-menarchal females: Negative pregnancy test at screening and willing to use two forms of contraception during the study
  6. Males engaging in sexual activity that could lead to pregnancy must use a condom.

Exclusion Criteria:

  1. Use of a statin, fibrate, or niacin within the 3 months prior to enrollment
  2. Have any chronic disease, except asthma, atopic dermatitis, autism or controlled seizure disorder
  3. Screening creatine phosphokinase (CK) ≥ 3x upper limit of normal for age
  4. Patient taking a CYP3A4 inhibitor (ie. cyclosporine or clarithromycin) in the last 7 days
  5. Patient has a history of allergy to atorvastatin or its derivatives
Sexes Eligible for Study: All
2 Years to 17 Years   (Child)
Contact: Jane C Burns, MD 858-246-0155 jcburns@ucsd.edu
Contact: Adriana Tremoulet, MD, MAS 858-246-0012 atremoulet@ucsd.edu
United States
Not Provided
Not Provided
Jane C. Burns, University of California, San Diego
University of California, San Diego
  • Children's Hospital Colorado
  • University of Colorado, Denver
Principal Investigator: Jane C Burns, MD University of California, San Diego
University of California, San Diego
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP